Subunitvaccines are often poorly immunogenic and require a strong adjuvant. Therefore,new adjuvant strategies are demanded to develop new vaccines. We formulated OVAand CpG-ODN with a nanostructure (Coa-ASC16) formed by self-assembly of6-O-ascorbyl palmitate. This nanoformulation (OCC) elicited strong humoral andcellular (CD4+andCD8+)responses, which are superior to those induced by a solution of OVA and CpG-ODN(OC). Nonetheless, some characteristics about action mechanism of Coa-ASC16remain to be elucidated. In this work we study some aspects about early immuneevents. Mice were subcutaneously immunized with OC or OCC formulation.Cytokines/chemokines were quantified in lymph nodes and serum at 0.33, 2, 24and 48 hours post-immunization by LEGENDplex Mouse Inflammation Panel 13-plex.We further determined by flow cytometry, OVA and CpG-ODN cellular uptake inlymph nodes 24 hours post-immunization. Lymph nodes of OCC immunized miceshowed higher levels of IFN-γ, IL-12p70,IL-1β, IL-10, IL-6, IL-27,IL-17A and IFN-β than mice immunized withOC (p<0.05).In contrast, OC immunized mice display higher levels of IFN-γ, TNF-α,MCP-1,IL-12p70 and IL-6 in serum than OCC immunized mice (p<0.05). Moreover, miceimmunized with OCC showed a higher absolute number of OVA+,CpG-ODN+andOVA+CpG-ODN+ monocytes(Ly6ChighLy6GCD11b+) anddendritic cells (Ly6C-Ly6G-CD11c+)than mice immunized with OC (p<0.05). In conclusion, the nanoformulation ofvaccine components modifies the cytokines/chemokines profile and promotes theco-uptake of antigen and immunostimulant by cells that infiltrate the lymphnode.